Baird Maintains Outperform on Cintas, Raises Price Target to $475

Morgan Stanley has decided to maintain its Equal-Weight rating of Haemonetics (NYSE:HAE) and raise its price target from $60.00 to $70.00. Shares of Haemonetics are trading up 1.46% over the last 24 hours, at $66.13 per share. A move to $70.00 would account for a 5.85% increase from the current share price.